"热点聚焦"标签列表

The Situation of Liver Diseases in Asian-Pacific countries and the Urgent Tasks for Beating HCV and HBV2016-03-01

New Threat to Developed Countries: NAFLD Related HCC 2016-03-01

Unmet Need for the Patients with Chronic Hepatitis C2016-03-01

Different Role of Liver Biopsy between Hepatitis B and C2016-03-01

Reality or Dream: to Eradicate Hepatitis C and Hepatitis B2016-03-01

[APASL前沿] HBV核心相关抗原可作为cccDNA的替代标志物2016-02-29

[APASL热点]大会报告：慢性乙型肝炎治疗新药REP21390-Ca使HBV RNA显著下降2016-02-29

[APASL前沿]二甲双胍对糖尿病/胰岛素抵抗的NASH-肝硬化患者疾病进程的影响2016-02-26

[APASL前沿]我国1～6岁儿童慢性丙型肝炎患者应用IFNα-2b+RBV治疗的SVR率高达90%以上2016-02-26

[APASL前沿]获得SVR后复发的2例患者伴有HCV基因型改变2016-02-26

[APASL前沿]研究发现治疗NASH和胆汁淤积的新型、高效非胆汁酸FXR激动剂2016-02-26

[APASL前沿]亚洲基因1型HCV感染者应用LDV/SOF治疗12周的SVR率高达99%2016-02-26

[APASL前沿]肝癌风险预测有望通过血液检测轻松完成2016-02-23

[APASL前沿] HBcrAg可作为cccDNA的替代标志物2016-02-22

[APASL前沿]HBV诱导的miRNA可影响HBsAg的生物学过程及表达2016-02-22

[APASL前沿]口服方案用于治疗基因1b型HCV感染者的TARGET中期分析2016-02-22

[APASL聚焦]亚太地区丙型肝炎治疗所面临的挑战2016-02-21

《WHO慢性乙型肝炎患者预防、关护和治疗指南》 推荐意见2016-01-04

NA长期治疗的HBeAg阳性慢乙肝患者可加用PEG-IFNα-2b治疗2015-12-23

[AASLD聚焦]我国首个无干扰素全口服DAA治疗基因1b型丙型肝炎的Ⅲ期临床中期结果在AASLD发布2015-11-17